We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

Pelletier J.;Radaelli M.;Comi G.;
2021-01-01

Abstract

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.
2021
8
8
1738
1744
Adult; Antibodies, Monoclonal, Humanized; COVID-19; Female; France; Humans; Immunologic Factors; Interferons; Italy; Male; Meta-Analysis as Topic; Middle Aged; Multiple Sclerosis; Multivariate Analysis; Protective Factors; Retrospective Studies; Risk Factors; Rituximab; Severity of Illness Index
Sormani M.P.; Salvetti M.; Labauge P.; Schiavetti I.; Zephir H.; Carmisciano L.; Bensa C.; De Rossi N.; Pelletier J.; Cordioli C.; Vukusic S.; Moiola L.; Kerschen P.; Radaelli M.; Theaudin M.; Immovilli P.; Casez O.; Capobianco M.; Ciron J.; Trojano M.; Stankoff B.; Creange A.; Tedeschi G.; Clavelou P.; Comi G.; Thouvenot E.; Battaglia M.A.; Moreau T.; Patti F.; De Seze J.; Louapre C.
File in questo prodotto:
File Dimensione Formato  
SORMANI.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 321.4 kB
Formato Adobe PDF
321.4 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1850573
Citazioni
  • ???jsp.display-item.citation.pmc??? 39
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 75
social impact